Volume : 12, Issue : 01, January – 2025
Title:
EVALUATION OF STRUCTURED INDIVIDUALIZED PHARMACIST INTERVENTION PROGRAMME ON ECONOMIC, CLINICAL AND HUMANISTIC OUTCOMES OF COPD PATIENTS IN A TERTIARY ROHINI SUPER SPECIALITY HOSPITAL
Authors :
Nallagatla Sai Kiran*, Dr.V. Umarani, DR.K. Nagasree, Dr.K. Shravankumar
Abstract :
Neonatal jaundice is a yellowish discoloration of the white part of the eyes and skin in a newborn baby due to high bilirubin levels. Other symptoms may include excess sleepiness or poor feeding. Complications may include seizures, cerebral palsy, or kernicterus. The need for treatment depends on bilirubin levels, the age of the child, and the underlying cause. Treatments may include more frequent feeding, phototherapy, or exchange transfusions. In those who are born early more aggressive treatment tends to be required. Physiologic jaundice generally lasts less than seven days. It aims to assess and manage the incidence of jaundice in neonates The study conducted, in neonates who are either born in primary care or discharged to primary care within the first few hours to days of life. A maternity care assistant (MCA) provides postpartum care to mother and neonate during daytime for the first 8 days after delivery. The MCA is supervised by a community midwife, who visits the family at least three times in the first week. Medical doctors are only involved in the care of otherwise healthy neonates if consulted by the community midwife. Jaundice is common in otherwise healthy neonates cared for in primary care. TSB quantification was not always performed in very jaundiced neonates, and not all neonates received phototherapy when indicated. Quality improvement initiatives are required, including alternative approaches to identifying potentially severe jaundice.
KEYWORDS: Maternity care assistant, Bilirubin levels, Community midwife, Neonates
Cite This Article:
Please cite this article in press Nallagatla Sai Kiran et al., Evaluation Of Structured Individualized Pharmacist Intervention Programme On Economic, Clinical And Humanistic Outcomes Of COPD Patients In A Tertiary Rohini Super Speciality Hospital.,Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
1. GOLD. Global initiative for chronic obstructive lung disease. Updated 2015. Available from www.goldcopd.org (Accessed 10 October 2015)
2. Benjamin MB. White paper on expanding the role of pharmacists in chronic obstructive pulmonary disease. J Am Pharm Assoc, 2011; 51: e20-e28.
3. Surulivelrajan M, Mathew J, Mohan KM, Rajesh V, Suhaj A. Study to Assess the Utility of Cloze test in Readability Assessment of Patient Information Leaflets in English and Indian Languages. Asian J. Pharm. Hea. Sci, 2013; 3:824-829
4. Mateti UV, Nagappa AN, Bairy M, Nagaraju SP, Attur RP. Pharmaceutical care for dialysis patients. Syst Rev Pharm, 2013; 4:1-6.
5. Khdour M, Kidney JC, Smyth BM, McElnay JC. Clinical Pharmacy –led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol 2009; 68:588-598.
6. Jarab AS, Salam GA, Khdour M, Shamssain M, Mukattash TL. Impact of Phamraceutical care on health outcomes in patients with COPD. Int J Clin Pharm 2012; 34:53-62.
7. Gupta D, Agarwal R, Agarwal AN, Maturu VN, Dhooria S, Prasad KT et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India, 2013;30:228-267.
8. Gallefoss F, Bakke PS, Rsgaard PK. Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1999; 159: 812–817.
9. Soler JJ, Martinez-Garcia MA, Roman P. Effectiveness of a specific program for patients with chronic obstructive pulmonary disease and frequent exacerbations. Arch Bronconeumol, 2006; 42:501–508.
10. Sanduzzi, Alessandro, Piero B, Piero C, Giousue AC, Paola C et al. COPD: adherence to therapy. Multidisciplinary respiratory medicine, 2014; 9: 60.
11. Haynes RB, Taylor DW, Sackett DL. Compliance in healthcare. Baltimore. Johns Hopkins University Press 1979; 1–7.
12. George J, David CM, Thoman R, Stewart K. Factors associated with medication nonadherence in Patients With COPD Chest 2005; 128:3198‐3204.
13. Dolce JJ, Crisp C, Manzella B, Richards JM, Hardin JM, Bailey WC. Medication adherence patterns in chronic obstructive pulmonary disease. Chest 1991; 99:837–841.
14. Balakrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clin Ther 2000; 22:452– 469.
15. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self- reported measure of medication adherence. Med Care 1986; 24: 67–74.